REG - Genedrive PLC - Short extension to NICE publication date

GenedriveAnnouncement

27/06/2024 09:30

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240627:nRSa1528Ua&default-theme=true

RNS Number : 1528U  Genedrive PLC  27 June 2024

genedrive plc

("genedrive" or the "Company")

 

Short extension to NICE publication date on CYP2C19 test

 

genedrive plc (AIM: GDR), the point-of-care pharmacogenetic testing company,
acknowledges, as announced on 3 April 2024, that the UK's National Institute
for Health and Care Excellence ("NICE") has recommended in draft guidance that
CYP2C19 genotyping should be used to guide clopidogrel use after Ischaemic
Stroke ("IS") or Transient Ischaemic Attack ("TIA"), and that the Genedrive®
CYP2C19-ID test should be used as the test of choice for point-of-care
strategies.

 

The final publication was expected by NICE on 10 July 2024, but the Company
notes from the NICE website that this has recently been extended to 31 July
2024. Further details can be found at:
 https://www.nice.org.uk/guidance/indevelopment/gid-dg10054/documents
(https://www.nice.org.uk/guidance/indevelopment/gid-dg10054/documents) .

 

For further details please contact:

 

 genedrive plc                                     +44 (0)161 989 0245
 James Cheek: CEO / Russ Shaw: CFO

 Peel Hunt LLP (Nominated Adviser and Broker)      +44 (0)20 7418 8900
 James Steel / Patrick Birkholm

 Walbrook PR Ltd (Media & Investor Relations)      +44 (0)20 7933 8780 or genedrive@walbrookpr.com
                                                   (mailto:genedrive@walbrookpr.com)
 Anna Dunphy                                       +44 (0)7876 741 001

 

About genedrive plc (http://www.genedriveplc.com). genedrive plc is a
pharmacogenetic testing company developing and commercialising a low cost,
rapid, versatile and simple to use point of need pharmacogenetic platform for
the diagnosis of genetic variants. This helps clinicians to quickly access key
genetic information that will aid them make the right choices over the right
medicine or dosage to use for an effective treatment, particularly important
in time-critical emergency care healthcare paradigms. Based in the UK, the
Company is at the forefront of point-of-care pharmacogenetic testing in
emergency healthcare. Pharmacogenetics informs on how your individual genetics
impact a medicines ability to work for you. Therefore, by using
pharmacogenetics, medicine choices can be personalised, made safer and more
effective. The Company has launched its two flagship products, the Genedrive®
MT-RNR1 ID Kit and the Genedrive® CYP2C19 ID Kit, both developed and
validated in collaboration with NHS partners and deployed on its point-of-care
thermocycler platform. Both tests are single-use disposable cartridges which
are ambient temperature stable, circumventing the requirement for cold chain
logistics. The Directors believe the Genedrive® MT-RNR1 ID Kit is a
worlds-first and allows clinicians to make a decision on antibiotic use in
neonatal intensive care units within 26 minutes, ensuring vital care is
delivered, avoiding adverse effects potentially otherwise encountered and with
no negative impact on the patient care pathway. Its CYP2C19 ID Kit which has
no comparably positioned competitor currently allows clinicians to make a
decision on the use of Clopidogrel in stroke patients in 70 minutes, ensuring
that patients who are unlikely to benefit from or suffer adverse effects from
Clopidogrel receive an alternative antiplatelet therapeutic in a timely
manner, ultimately improving outcomes. Both tests have undergone review by the
National Institute for Health and Care Clinical Excellence ("NICE") and have
been recommended for use in the UK NHS.  The Company has a clear commercial
strategy focused on accelerating growth through maximising in-market sales,
geographic and portfolio expansion and strategic M&A, and operates out of
its facilities in Manchester.

 

The Company has a clear commercial strategy focused on accelerating growth
through maximising in-market sales, geographic and portfolio expansion and
strategic M&A, and operates out of its facilities in Manchester.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCFIFFTRDIDFIS